论文部分内容阅读
目的观察低分子肝素 ( LMWH)对老年肾病综合征治疗的有效性和安全性。方法对 46例老年肾病综合征患者根据其年龄、病程和病理类型随机分为两组 ,对照组常规给予泼尼松、贝那普利治疗 ,而 L MWH治疗组在上述治疗药物的基础上加用 LMWH5 0 0 0 IU皮下注射 ,每日 1次。结果治疗 6周后 LMWH组尿蛋白、血脂、FIB、D-二聚体明显减少 ,血浆白蛋白明显回升 ,其中尿蛋白 ,血白蛋白 ,FIB和 D-二聚体变化与对照组相比有显著性差异 ( P<0 .0 5 ) ,而血脂和肾功能无显著性变化 ( P>0 .0 5 ) ,未见有明显皮肤粘膜出血等副作用。结论 LMWH是老年肾病综合征有效、安全的首选抗凝药物。
Objective To observe the efficacy and safety of low molecular weight heparin (LMWH) in the treatment of senile nephrotic syndrome. Methods 46 cases of elderly patients with nephrotic syndrome were randomly divided into two groups according to their age, course of disease and pathological type. The control group was given conventional prednisone and benazepril treatment, and L MWH treatment group on the basis of the above treatment Subcutaneous injection with LMWH5000 IU once daily. Results After 6 weeks of treatment, the levels of urinary protein, lipids, FIB and D-dimer in LMWH group were significantly decreased and plasma albumin was significantly increased. The changes of urinary protein, albumin, FIB and D-dimer in LMWH group were (P <0.05), while there was no significant change in serum lipid and renal function (P> 0.05). No obvious side effects such as mucocutaneous bleeding were observed. Conclusion LMWH is an effective and safe anticoagulant drug for senile nephrotic syndrome.